

Form PTO-1449 (modified)

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No.

UTSD:521/WIM

Serial No.

09/112,041

Applicant

Maria-Ana Ghetie et al.

Filing Date:

July 8, 1998

Group:

1642

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1						

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
ON	B1						

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
ON	C66	Caron <i>et al.</i> , "Engineered humanized dimeric forms of IgG are more effective antibodies," <i>J. Exp. Med.</i> , 176:1191-1195, Oct. 1992.
ON	C67	Hudson, "Recombinant antibody constructs in cancer therapy," <i>BioTechnology</i> , 12:548-555, July 1994.
ON	C68	Mota <i>et al.</i> , "Preparation and some properties of dimeric rabbit IgG antibody," <i>Mol. Immunol.</i> , 21(7):641-645, 1984.
ON	C69	Shopes, "A genetically engineered human IgG mutant with enhanced cytolytic activity," <i>Mol. Immunol.</i> , 148(9):2918-2922, May 1992.
ON	C70	Shuford <i>et al.</i> , "Effect of light chain V region duplication on IgG oligomerization and in vivo efficacy," <i>Science</i> , 252(5006):724-7, May 1991.
ON	C71	Smith and Morrison, "Recombinant polymeric IgG: an approach to engineering more potent antibodies," <i>BioTechnology</i> , 12:683-688, July 1994.
ON	C72	Smith <i>et al.</i> , "Addition of a μ -tailpiece to IgG results in polymeric antibodies with enhanced effector functions including complement-mediated cytotoxicity by IgG4," <i>J. Immunol.</i> , 154:2226-2236, 1995.
ON	C73	Wolff <i>et al.</i> , "Monoclonal antibody homodimers: enhanced antitumor activity in nude mice," <i>Can. Res.</i> , 53:2560-2565, June 1993.

EXAMINER:

Jennifer Nichols

DATE CONSIDERED:

1/16/2000

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)



List of Patents and Publications for Applicant
 INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No.

UTSD:521/WIM

Serial No.

09/112,041

Applicant

Maria-Ana Ghetie et al.

Filing Date:

July 8, 1998

Group:

1642

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C74	Wolff <i>et al.</i> , "Human monoclonal antibody homodimers: effect of valency on in vitro and in vivo antibacterial activity," <i>J. Immunol.</i> , 148(8):2469-2474, April 1992.

EXAMINER:

Jennifer Nichols

DATE CONSIDERED:

1/16/2000

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)

Atty. Docket No.

Serial No.

UTSD:521/WIM

09/112,041

U.S. Department of Patents and Publications for Applicant's

Applicants

Maria-Ana Ghetie, Jonathan W. Uhr
and Ellen S. Vitetta**INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)

Filing Date:

July 8, 1998

Group:

1643

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date if App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
1	B1	WO 92/04053	03/19/92	PCT	—	—	—

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
1	C1	Adair, "Engineering antibodies for therapy," <i>Immunol. Rev.</i> , 192; 130:5-40, 1992.
2	C2	Akiyama <i>et al.</i> , "Fibronectin and integrins in invasion and metastasis," <i>Cancer Metastasis Rev.</i> , 14:173-189, 1995.
3	C3	Beckwith <i>et al.</i> , "Anti-IgM mediated growth inhibition of a human B-lymphoma cell line is independent of phosphatidylinositol turnover and protein kinase C activation and involves tyrosine phosphorylation," <i>J. Immunol.</i> , 147:2411-2418, 1991.
4	C4	Bridges <i>et al.</i> , "Selective <i>in vivo</i> antitumor effect of monoclonal anti-I-A antibody on B cell lymphoma," <i>J. Immunol.</i> , 139:4242-4249, 1987.
5	C5	Brown <i>et al.</i> , "Antiidiotype antibody therapy of B-cell lymphoma," <i>Semin. Oncol.</i> , 16:199-210, 1989.
6	C6	Brunner <i>et al.</i> , "Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas," <i>Nature</i> , 373:441-444, 1995.
7	C7	Caron <i>et al.</i> , "Engineered humanized dimeric forms of IgG are more effective antibodies", <i>J. Exp. Med.</i> , 176:1191-1195, 1992.
8	C8	Cumber <i>et al.</i> , "Comparative stabilities in vitro and in vivo of a recombinant mouse antibody FvCys fragment and a bisFvCys conjugate," <i>J. Immunol.</i> , 149(1):120-126, 1992.

Examiner:

Jennifer Nichols

Date Considered:

1/16/2000

EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Information Disclosure Statement — PTO-1449 (Modified)

Form PTO-1449 (modified)

Atty. Docket No.

UTSD:521/WIM

Serial No.

09/112,041

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicants

Maria-Ana Ghetie, Jonathan W. Uhr
and Ellen S. Vitetta

Filing Date:

July 8, 1998

Group:

1643

U.S. Patent Documents

See Page 1














Foreign Patent Documents

See Page 1

Other Art

See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C9	Denkers <i>et al.</i> , "Influence of antibody isotype of passive serotherapy of lymphoma," <i>J. Immunol.</i> , 135:2183-2186, 1995.
	C10	Dhein <i>et al.</i> , "Autocrine T-cell suicide mediated by APO-1/(Fas/CD95)," <i>Nature</i> , 373:438-441, 1995.
	C11	Dillman, "Antibodies a cytotoxic therapy," <i>J. Clin. Oncol.</i> , 12(7):1497-1515, 1994.
	C12	Dyer <i>et al.</i> , "Effects of CAMPATH-1 antibodies <i>in vivo</i> in patients with lymphoid malignancies: Influence of antibody isotype," <i>Blood</i> , 73:1431-1439, 1989.
	C13	Edward, "Integrins and other adhesion molecules involved in melanocytic tumor progression," <i>Curr. Opin. Oncol.</i> , 7:185-191, 1995.
	C14	Funakoshi <i>et al.</i> , "Inhibition of human B-cell lymphoma growth by CD40 stimulation," <i>Blood</i> , 83:2787-2794, 1994.
	C15	Ghetie <i>et al.</i> , "The use of immunoconjugates in cancer therapy," <i>Exp. Opin. Invest. Drugs.</i> , 5(3):309-321, 1996.
	C16	Ghetie <i>et al.</i> , "Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for <i>in vivo</i> therapy," <i>Cancer Res.</i> , 48:2610-2617, 1988.
	C17	Ghetie <i>et al.</i> , "Anti-CD19 inhibits the growth of human B-cell tumor lines <i>in vitro</i> and of Daudi cells in SCID mice by inducing reversible cell cycle arrest," <i>Blood</i> , 83:1329-1336, 1994.
	C18	Ghetie <i>et al.</i> , "Combination immunotoxin treatment and chemotherapy in SCID mice with advanced, disseminated Daudi lymphoma," <i>Int. J. Cancer</i> , 68:93-96, 1996.
	C19	Ghetie <i>et al.</i> , "Disseminated or localized growth of a human B-cell tumor (Daudi) in SCID mice," <i>Int. J. Cancer</i> , 45:481-485, 1990.
	C20	Ghetie <i>et al.</i> , "The GLP large scale preparation of immunotoxins containing deglycosylated ricin A chain and a hindered disulfide bond," <i>J. Immunol. Methods</i> , 142:223-230, 1991.
	C21	Ghetie <i>et al.</i> , "Eradication of minimal disease in severe combined immunodeficient mice with disseminated Daudi lymphoma using chemotherapy and an immunotoxin cocktail," <i>Blood</i> , 84:702-707, 1994.

Examiner:

Jennifer Nichols

Date Considered:

1/18/2000

EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Information Disclosure Statement — PTO-1449 (Modified)

Form PTO-1449 (modified)

Atty. Docket No.

UTSD:521/WIM

Serial No.

09/112,041

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicants

Maria-Ana Ghetie, Jonathan W. Uhr
and Ellen S. Vitetta

Filing Date:

July 8, 1998

Group:

1643

U.S. Patent Documents

See Page 1














Foreign Patent Documents

See Page 1

Other Art

See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C22	Ghetie <i>et al.</i> , "The anti-tumor activity of an anti-CD22-immunotoxin in SCID mice with disseminated Daudi lymphoma is enhanced by either an anti-CD19 antibody or an anti-CD19 immunotoxin," <i>Blood</i> , 80:2315-2320, 1992.
	C23	Greenwood <i>et al.</i> , "Engineering multiple-domain forms of the therapeutic antibody CAMPATH-IH: Effects on complement lysis", <i>Therap. Immunol.</i> , 1:247-255, 1994.
	C24	Guo <i>et al.</i> , "Inhibition of human melanoma growth and metastasis in vivo by anti-CD44 monoclonal antibody," <i>Cancer Res.</i> , 54:1561-1565, 1994.
	C25	Hale <i>et al.</i> , "Therapeutic potential of rat monoclonal antibodies: Isotype specificity of antibody-dependent cell-mediated cytotoxicity with human lymphocytes," <i>J. Immunol.</i> , 134:3056-3061, 1985.
	C26	Hale <i>et al.</i> , "Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody," <i>Lancet</i> , 2:1394-1399, 1988.
	C27	Hamblin <i>et al.</i> , "Preliminary experience in treating lymphocytic leukaemia with antibody to immunoglobulin idiotypes on the cell surfaces," <i>Br. J. Cancer</i> , 42:495-502, 1980.
	C28	Hamblin <i>et al.</i> , "Initial experience in treating human lymphoma with a chimeric univalent derivative of monoclonal anti-idiotypic antibody," <i>Blood</i> , 69:790-797, 1987.
	C29	Hekman <i>et al.</i> , "Initial experience with treatment of human B cell lymphoma with anti-CD19 monoclonal antibody," <i>Cancer Immunol., Immunother.</i> , 32:364-372, 1991.
	C30	Herlyn and Koprowski, "IgG2a monoclonal antibodies inhibit human tumor growth through interaction with effector cells," <i>Proc. Natl. Acad. Sci. USA</i> , 79:4761-4765, 1982.
	C31	Hooijberg <i>et al.</i> , "Enhanced antitumor effects of CD20 over CD19 monoclonal antibodies in a nude mouse xenograft model," <i>Cancer Res.</i> , 55(4):840-846, 1995.
	C32	Hooijberg <i>et al.</i> , "Eradication of large human B cell tumors in nude mice with unconjugated CD20 monoclonal antibodies and interleukin 2," <i>Cancer Res.</i> , 55(12):2627-2634, 1995.
	C33	Ju <i>et al.</i> , "Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation," <i>Nature</i> , 373:444-448, 1995.
	C34	Kaminski <i>et al.</i> , "Importance of antibody isotype in monoclonal anti-idiotypic therapy of a murine B-cell lymphoma," <i>J. Immunol.</i> , 136:1123-1130, 1986.

Examiner:

Jennifer Nichols

Date Considered:

1/14/2000

EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Information Disclosure Statement — PTO-1449 (Modified)

Form PTO-1449 (modified)

Atty. Docket No.

Serial No.

UTSD:521/WIM

09/112,041

List of Patents and Publications for Applicant's

Applicants

Maria-Ana Ghetie, Jonathan W. Uhr
and Ellen S. Vitetta**INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)

Filing Date:

July 8, 1998

Group:

1643

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C35	Kaminski <i>et al.</i> , "Radioimmuno-therapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody," <i>N. Engl. J. Med.</i> , 329:459-465, 1993.
	C36	Marches <i>et al.</i> , "Tumor dormancy and cell signaling III: Role of hypercrosslinking of IgM and CD40 on the induction of cell cycle arrest and apoptosis in B lymphoma cells," <i>Therap. Immunol.</i> , 2:125-136, 1996.
	C37	Meeker <i>et al.</i> , "A clinical trial of anti-idiotypic therapy for B cell malignancy," <i>Blood</i> , 65:1349-1363, 1985.
	C38	Page and Defranco, "Role of phosphoinositide-derived second messengers in mediated anti-IgM-induced growth arrest of WEHI-231 B lymphoma cells," <i>J. Immunol.</i> , 140:3717-26, 1988.
	C39	Press <i>et al.</i> , "Monoclonal antibody 1 F5 (anti-CD20) serotherapy of human B cell lymphomas," <i>Blood</i> , 69:584-591, 1987.
	C40	Press <i>et al.</i> , "Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support," <i>N. Engl. J. Med.</i> , 329:1219-1224, 1993.
	C41	Qi <i>et al.</i> , "Antibody-targeted lymphokine-activated killer cells inhibit liver micrometastases in severe combined immunodeficient mice," <i>Gastroenterology</i> 109(6):1950-1957, 1995.
	C42	Racila <i>et al.</i> , "Tumor dormancy and cell signaling: Anti- μ -induced apoptosis in human B-lymphoma cells is not caused by an APO-1 - APO-1 ligand interaction," <i>Proc. Natl. Acad. Sci., USA</i> , 93:2165-2168, 1996.
	C43	Racila <i>et al.</i> , "Tumor dormancy and cell signaling. II. Antibody as an agonist in inducing dormancy of a B cell lymphoma in SCID mice," <i>J. Exp. Med.</i> , 181:1539-1550, 1995.
	C44	Rankin <i>et al.</i> , "Treatment of two patients with B-cell lymphoma with monoclonal anti-idiotypic antibodies," <i>Blood</i> , 65:1373-1381, 1985.
	C45	Riethmüller <i>et al.</i> , "Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma," <i>Lancet</i> 343:1174-1177, 1994.
	C46	Schreiber <i>et al.</i> , "An unmodified anticarcinoma antibody, BR96, localizes to and inhibits the outgrowth of human tumors in nude mice," <i>Cancer Res.</i> , 52:3262-3266, 1992.

Examiner:

Jenny for Nichols

Date Considered:

1/16/2000

EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Information Disclosure Statement — PTO-1449 (Modified)

Form PTO-1449 (modified)

Atty. Docket No.

UTSD:521/WIM

Serial No.

09/112,041

List of Patents and Publications for Applicant's

Applicants

Maria-Ana Ghetie, Jonathan W. Uhr
and Ellen S. Vitetta**INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)

Filing Date:

July 8, 1998

Group:

1643

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C47	Scott <i>et al.</i> , "Lymphoma models for B-cell activation and tolerance. II. Growth inhibition by anti-m of WEHI-231 and the selection and properties of resistant mutants", <i>Cell Immunol.</i> , 93:124-131, 1985.
	C48	Scott <i>et al.</i> , "T cells commit suicide, but B cells are murdered," <i>J. Immunol.</i> , 156:2352-2356, 1996.
	C49	Shopes, "A genetically engineered human IgG mutant with enhanced cytolytic activity," <i>J. Immunol.</i> , 148(9):2918-2922, 1992.
	C50	Shuford <i>et al.</i> , "Effect of light chain V region duplication on IgG oligomerization and <i>in vivo</i> efficacy", <i>Science</i> 252:724-727, 1991.
	C51	Smith and Morrison, "Recombinant polymeric IgG: An approach to engineering more potent antibodies", <i>Bio/Technol.</i> , 12:683-688, 1994.
	C52	Trauth <i>et al.</i> , "Monoclonal antibody-mediated tumor regression by induction of apoptosis," <i>Science</i> , 245:301-305, 1989.
	C53	Vitetta and Uhr, "Monoclonal antibodies as agonists: an expanded role for their use in cancer therapy," <i>Cancer Res.</i> , 54:5301-5309, 1994.
	C54	Wolff <i>et al.</i> , "Human monoclonal antibody homodimers", <i>J Immunol.</i> , 148:2469-2474, 1992.
	C55	Wolff <i>et al.</i> , "Monoclonal antibody homoconjugates: Enhanced antitumor activity in nude mice", <i>Cancer Res.</i> , 53:2560-2565, 1993.
	C56	Yefenof <i>et al.</i> , "Cancer dormancy: Isolation and characterization of dormant lymphoma cells," <i>Proc. Natl. Acad. Sci., USA</i> , 90:1829-1833, 1993.
	C57	Zahalka <i>et al.</i> , "Lymph node (but not spleen) invasion by murine lymphoma is both CD44- and hyaluronate-dependent," <i>J. Immunol.</i> , 154:5345-5355, 1995.

Examiner:

Jennifer Nichols

Date Considered:

1/16/2000

EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Information Disclosure Statement — PTO-1449 (Modified)

Form PTO-1449 (modified)		Atty. Docket No. UTSD:521/WIM	Serial No. 09/112,041
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicants Maria-Ana Ghetie, Jonathan W. Uhr and Ellen S. Vitetta	
		Filing Date: July 8, 1998	Group: 1643
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 1	Other Art See Page 1	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date if App.
	A1	5,686,072	11/11/97	Uhr <i>et al.</i>	—	—	—

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
<i>W</i>	B2	EP 0468637	01/29/92	Europe	—	—	—
<i>W</i>	B3	EP 0453082	10/23/91	Europe	—	—	—
<i>W</i>	B4	EP 0404097	12/27/90	Europe	—	—	—
<i>W</i>	B5	WO 91/03493	03/21/91	PCT	—	—	—

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
<i>W</i>	C63	International Search Report dated January 15, 1999 (PCT/US98/14222)(UTFD:521P).
<i>W</i>	C64	Kita <i>et al.</i> , "ERBB receptor activation, cell morphology changes, and apoptosis induced by anti-HER2 monoclonal antibodies," <i>Biochem. Biophys. Res. Comm.</i> , 226(1):59-69, 1996.
<i>W</i>	C65	Wu <i>et al.</i> , "Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin," <i>J. Clin. Invest.</i> , 95(4):1897-1905, 1995.

Examiner: *Jenni for Nichols* Date Considered: *1/16/2000*

EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Information Disclosure Statement — PTO-1449 (Modified)

Form PTO-1449 (modified)

Atty. Docket No.

UTSD:521/WIM

Serial No.

09/112,041

List of Patents and Publications for Applicant's

Applicants

Maria-Ana Ghetie, Jonathan W. Uhr
and Ellen S. Vitetta**INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)

Filing Date:

July 8, 1998

Group:

1643

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1






U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date if App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C58	Hellström <i>et al.</i> , "Immunoconjugates and Immunotoxins for Therapy of Carcinomas," <i>Adv. Pharmacol.</i> , 33:349-388, 1995.
	C59	Levy and Miller, "Therapy of lymphoma directed at idiotypes", <i>J. Natl. Cancer Inst. Monographs</i> , 10:61-68, 1990.
	C60	Morrison and Oi, "Genetically engineered antibody molecules," <i>Adv. Immunol.</i> , 44:65-91, 1989.
	C61	Ruiz <i>et al.</i> , "Suppression of mouse melanoma metastasis by EA-1, a monoclonal antibody specific for α_6 integrins," <i>Cell Adhes. Commun.</i> , 1:67-81, 1993.
	C62	Waldmann, "Immune receptors: Targets for therapy of leukemia/lymphoma, autoimmune diseases and for the prevention of allograft rejection," <i>Annu. Rev. Immunol.</i> , 10:675-704, 1992.

Examiner: *Jennifer Nichols*Date Considered: *1/16/2000*

EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.